医学
内科学
放射治疗
佐剂
比例危险模型
阶段(地层学)
辅助治疗
肿瘤科
淋巴结
化疗
病态的
肺癌
多元分析
回顾性队列研究
外科
古生物学
生物
作者
Jing Yu,Wen Ouyang,Zhihao Huang,G Chen,Yunfeng Zhou,Y L Mao,J H Zhang,Chengying Xie
出处
期刊:PubMed
日期:2020-04-23
卷期号:42 (4): 336-339
标识
DOI:10.3760/cma.j.cn112152-20190626-00397
摘要
Objective: To investigate the outcomes of limited stage small cell lung cancer (L-SCLC) undergoing surgical therapy and to explore the value of adjuvant therapy for those patients. Methods: A retrospective analysis was initialed for the L-SCLC patients who underwent the surgical treatment in the Zhongnan Hospital of Wuhan University from January 2012 to December 2018. The median disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method. Cox regression was used to explore the prognostic factors. Results: A total of 44 patients were included in our study. The median DFS was 25 months, 1- and 2-year DFS rate were 70.2% and 51.9%, respectively. The median OS was 41 months, 1- and 2- year OS rate were 88.4% and 69.9%, respectively. Multivariate analysis showed male (RR=6.56, P=0.03), T3-4 (RR=6.23, P=0.01), pathological lymph node metastasis (RR=6.52, P=0.03) and adjuvant radiotherapy (RR=0.13, P=0.002) were associated with disease relapse significantly. Moreover, pathological lymph node metastasis (RR=3.62, P=0.01) coupled with sufficient adjuvant chemotherapy (≥4 cycles) (RR=0.12, P=0.01) were independent prognostic factors of OS. Conclusions: Surgical therapy may be an alternative primary treatment for L-SCLC. Additional adjuvant radiotherapy can reduce the risk of recurrence. Giving sufficient course of adjuvant chemotherapy can improve OS.目的: 探讨局限期小细胞肺癌患者手术治疗的疗效以及术后辅助治疗的价值。 方法: 收集2012年1月至2018年12月间在武汉大学中南医院完成根治性手术切除的44例局限期小细胞肺癌患者的临床资料。采用Kaplan-Meier方法分析患者的中位无疾病进展生存时间(DFS)和中位总生存时间(OS),采用Cox回归模型分析患者预后的影响因素。 结果: 全组患者的中位DFS为25个月。患者的1、2年无疾病进展生存率分别为70.2%和51.9%。患者的中位生存期为41个月,患者的1、2年总生存率分别为88.4%和69.9%。多因素分析显示,男性(RR=6.56, P=0.03)、T分期(RR=6.23, P=0.01)、N分期(RR=6.52, P=0.03)和胸部辅助放疗(RR=0.13, P=0.002)为影响患者术后复发的独立因素。N分期(RR=3.62, P=0.01)和辅助化疗周期数(RR=0.12, P=0.01)为影响患者预后的独立因素。 结论: 手术可能是局限期小细胞肺癌的一种可选择的初始治疗方式,辅助放疗可减少术后复发的风险,完成足疗程的辅助化疗可使患者生存获益。.
科研通智能强力驱动
Strongly Powered by AbleSci AI